Cel-Sci
Update in progressCVM (NYSE American)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
CEL-SCI Corporation is a clinical-stage biotechnology company focused on cancer and immune-related diseases in the United States. Its lead immunotherapy, Multikine, has completed Phase III trials for certain head and neck cancers. It also develops LEAPS, a patented T-cell modulation platform to stimulate the immune system against infections, autoimmune conditions, allergies, transplantation rejection, and cancer, with potential rheumatoid arthritis use. LEAP candidates CEL-2000, CEL-4000, and CEL-5000 are in preclinical development. The company has a strategic partnership with Saudi Arabian Pharmaceutical Company for Multikine in head and neck cancer. Founded in 1983, based in Vienna, Virginia.
Company score
- Sentiment
- 0.33
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.22
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE American (ASE)
- LocationUnited States
- CEOMr. Geert R. Kersten Esq.
- Founded1983
- Websitecel-sci.com
Identifiers
- ISINUS1508377066
- FIGIBBG000H5G6L5
- CUSIP150837409
- CIK0000725363